Autoinjectors Market - 2024-2033

March 2025 | 219 pages | ID: A5B529A569B1EN
DataM Intelligence

Abstracts

The Autoinjectors Market was valued at US$ 10.37 billion in 2024 and is anticipated to reach US$ 39.84 billion by 2033, at a CAGR of 0.172 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Autoinjectors Market.

This report delivers a comprehensive overview of the Autoinjectors Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Autoinjectors Market. The Autoinjectors Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Autoinjectors Market Scope:

By Type

• Disposable Autoinjectors
• Reusable Autoinjectors

By Technology

• Manual Autoinjectors
• Automated Autoinjectors

By Route of Administration

• Intramuscular
• Intravenous and Subcutaneous

By Therapy

• Rheumatoid Arthritis
• Multiple Sclerosis
• Diabetes
• Anaphylaxis
• Others

By End-User

• Hospitals
• Home Care Setting
• Ambulatory Surgical Centers

Key Players

• Eli Lilly and Company
• SHL Medical AG
• Amgen Inc.
• Owen Mumford Ltd.
• Ypsomed AG
• Teva Pharmaceutical Industries Ltd.
• Biogen
• Mylan Inc.
• Pfizer Inc.
• Sanofi

Major Highlights

This report delivers a comprehensive overview of the Autoinjectors Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Autoinjectors Market. The Autoinjectors Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Type
3.2. Snippet by Technology
3.3. Snippet by Route of Administration
3.4. Snippet by Therapy
3.5. Snippet by End-User
3.6. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
  4.1.2. Increasing Regulatory Approvals and Launches for Autoinjectors
  4.1.3. Restraints
  4.1.4. High Cost of Auto-Injectors
  4.1.5. Opportunity
  4.1.6. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. BY TYPE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  6.1.2. Market Attractiveness Index, By Type
6.2. Disposable Autoinjectors*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Reusable Autoinjectors

7. BY TECHNOLOGY

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  7.1.2. Market Attractiveness Index, By Technology
7.2. Manual Autoinjectors*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Automated Autoinjectors

8. BY ROUTE OF ADMINISTRATION

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Intramuscular*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Intravenous and Subcutaneous

9. BY THERAPY

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  9.1.2. Market Attractiveness Index, By Therapy
9.2. Rheumatoid Arthritis*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Multiple Sclerosis
9.4. Diabetes
9.5. Anaphylaxis
9.6. Others

10. BY END-USER

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Home Care Setting
10.4. Ambulatory Surgical Centers

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Type
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  11.2.9. The U.S.
  11.2.10. Canada
  11.2.11. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Type
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  11.3.9. Germany
  11.3.10. UK
  11.3.11. France
  11.3.12. Italy
  11.3.13. Spain
  11.3.14. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Type
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  11.4.9. Brazil
  11.4.10. Argentina
  11.4.11. Rest of South America
11.5. Asia-Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Type
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  11.5.9. China
  11.5.10. India
  11.5.11. Japan
  11.5.12. South Korea
  11.5.13. Rest of Asia-Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Type
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

13.1. Eli Lilly and Company*
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Financial Overview
  13.1.4. Key Developments
13.2. SHL Medical AG
13.3. Amgen Inc.
13.4. Owen Mumford Ltd.
13.5. Ypsomed AG
13.6. Teva Pharmaceutical Industries Ltd.
13.7. Biogen
13.8. Mylan Inc.
13.9. Pfizer Inc.
13.10. Sanofi (*LIST NOT EXHAUSTIVE)

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us